Business
Biohaven is a biopharmaceutical company focused on immunology, neuroscience, and oncology.
Biohaven cut the net loss but burned more cash, while insiders bought heavily into a narrowed late-stage pipeline.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage biopharma pipelineNote
- Loss — Net loss narrowed 12.7%OK
- Cash burn — FCF deficit widened to $610.2MWatch
- Equity — Equity down 87.7%Watch
- SBC — Stock comp up 56.1%Watch
- Insiders — $30.6M purchases / 0 salesOK
- Accounting — Forensic screens unavailableNote
Leadership changes
From Biohaven Ltd.'s own filings, the day they're filed.
- David Pirman · President · appointmenteff. 2026-07-13
Latest filings
- 8-K · Company announcement2026-08-26
- 8-K · Company announcement2026-08-10
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-07-09
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Biohaven Ltd., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.